Beam's base editing sickle cell therapy clears pivotal trial

Overview

Updated 1 hour ago

Beam Therapeutics said Tuesday that its sickle cell treatment, risto-cel, met the main goal of a late-stage trial: patients stayed free of severe pain crises for at least 12 months. It is the first positive late-stage result for base editing, a gene-editing method that changes individual DNA letters without cutting the strand. Beam plans to file for FDA approval as early as the end of 2026.

The result puts a third gene therapy into reach for a disease that already has two approved cures, Casgevy and Lyfgenia. Both have sold slowly since approval, and one developer, Bluebird Bio, sold itself after struggling to market its therapy. Beam argues risto-cel's shorter manufacturing and fewer cell-collection cycles address the bottleneck that has limited uptake.

Why it matters

A third gene therapy for sickle cell, and the first using base editing, is nearing the market with a faster-to-manufacture option.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

Patients in the pivotal analysis

Treated patients with 12 months of follow-up as of Oct. 20, 2026.

Months free of severe pain crises

The primary endpoint required freedom from severe vaso-occlusive crises for at least 12 consecutive months.

>60%

Mean fetal hemoglobin (HbF)

The protective, non-sickling hemoglobin the edit is designed to switch on.

<40%

Mean pathologic hemoglobin S (HbS)

The sickling hemoglobin, reduced below the level seen in many patients.

$219M

Casgevy sales, first nine months 2026

Revenue for the competing CRISPR therapy, showing the market risto-cel would enter.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

John Evans

Chief Executive Officer, Beam Therapeutics

Leading Beam through its first regulatory filing

Organizations Involved

Beam Therapeutics

Biotechnology company

Preparing an FDA application for risto-cel

Cambridge, Massachusetts biotech developing precision base-editing therapies.

Vertex Pharmaceuticals and CRISPR Therapeutics

Pharmaceutical partnership

Markets Casgevy, the first approved CRISPR therapy for sickle cell

Partners behind Casgevy, the CRISPR-based sickle cell gene therapy approved in 2023.

Genetix Biotherapeutics

Gene therapy company

Markets Lyfgenia; formerly Bluebird Bio

Formerly Bluebird Bio, maker of the sickle cell gene therapy Lyfgenia.

Timeline

December 2023 November 2026

5 events Latest: Yesterday

Tap a bar to jump to that date

November 2026
Risto-cel meets pivotal trial goal
Latest Data

31 patients free of severe pain crises for 12 months; Beam plans FDA filing by year-end.
Yesterday
Beam announces ASH oral presentation
Statement

Company says updated data and patient-reported outcomes will be presented in December.
7 days ago
December 2025
Updated 31-patient data at ASH
Data

Mean fetal hemoglobin above 60%, durable up to 20 months, no severe crises after engraftment.
December 6th, 2025
June 2025
Beam presents early risto-cel data at EHA
Data

Interim results show rising fetal hemoglobin in treated patients.
June 2025
December 2023
First gene therapies for sickle cell approved
Regulatory

Casgevy and Lyfgenia reach the market, giving patients two gene-editing options.
December 2023

Scenarios

FDA approves risto-cel, making it the third gene therapy for sickle cell

Likely Resolves by End of 2027

Discussed by: Beam management and RBC Capital Markets analysts

Beam submits its biologics license application by the end of 2026 and the FDA grants approval, likely after a priority or standard review. Risto-cel would become the first approved base-editing therapy and the third gene therapy for sickle cell, joining Casgevy and Lyfgenia.

FDA issues a complete response letter, delaying risto-cel

Possible Resolves by End of 2027

Discussed by: Biotechnology analysts covering Beam

Regulators ask for more manufacturing or follow-up data instead of approving. Beam would need to run additional studies or fix production issues, pushing the launch past 2027 and giving Casgevy more time to entrench.

Risto-cel launches but uptake stays slow, as with Casgevy and Lyfgenia

Possible Resolves by Q2 2028

Discussed by: RBC Capital Markets analysts and Beam management

Approval arrives, but few patients receive the therapy in its first year. The bottleneck could be cost, treatment center capacity, or the burden of chemotherapy conditioning. Beam argues its shorter manufacturing will avoid the supply constraints that slowed rivals.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

December 2023

First CRISPR therapy approval (December 2023)

The FDA approved Casgevy, the first therapy built on CRISPR gene editing, for sickle cell disease. It was a scientific first: a treatment that edits a patient's DNA to switch on fetal hemoglobin.

Then

Only five patients received Casgevy in the second half of 2024.

Now

Uptake climbed to 64 patients in 2025 and produced $219 million in sales through September 2026, but the slow start showed how hard gene therapies are to deliver.

Why this matters now

Risto-cel would be the second gene-editing approach and the third product in the same market, facing the same delivery bottlenecks.

2025

Bluebird Bio's gene therapy retreat (2025)

Bluebird Bio, which sold Lyfgenia for sickle cell, struggled to market the therapy and its other gene treatments. The company sold itself, later operating as Genetix Biotherapeutics.

Then

Lyfgenia remained on the market but with limited reach.

Now

The sale became a cautionary example of how approval does not guarantee a commercial market for one-time gene therapies.

Why this matters now

Beam will face the same question: whether a better manufacturing process is enough to overcome the cost and logistics that slowed earlier products.